Skip to main content
. 2021 May 21;51(8):992–1005. doi: 10.1111/cea.13885

FIGURE 1.

FIGURE 1

Anti‐IL5/IL5Rα mechanism of action. With permission from NSAN (www.nordstar‐NSAN.com). Monoclonal antibodies inhibit eosinophils functions directly neutralizing IL‐5 (Mepolizumab and Reslizumab) or targeting and blocking the IL‐5 receptor on eosinophils surface (Benralizumab)